Nafarelin: a new medical therapy for endometriosis.
Henzl
M R
MR
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco.
Monroe
S E
SE
D000281:Administration, Intranasal; D000284:Administration, Oral; D000328:Adult; D015519:Bone Density / Q000187:drug effects; D002979:Climacteric / Q000187:drug effects; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D017274:Nafarelin; D012449:Safety
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D003613:Danazol